MedTrace Logo

A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence

NCT00749632 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2009-10-15

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of three doses of oxybutynin for the treatment of urge urinary incontinence.

Conditions

  • Urinary Incontinence, Urge

Interventions

DRUG

oxybutynin

low dose oxybutynin administered daily

DRUG

oxybutynin

middle dose oxybutynin administered daily

DRUG

oxybutynin

high dose oxybutynin administered daily

Sponsors & Collaborators

  • FemmePharma Global Healthcare, Inc.

    lead INDUSTRY

Principal Investigators

  • Peter K. Mays, Ph.D. · FemmePharma Global Healthcare, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00749632 on ClinicalTrials.gov